[go: up one dir, main page]

NO303265B1 - Xantinderivater samt anvendelse av xantinderivater for fremstilling av et terapeutisk middel mot Parkinson's sykdom - Google Patents

Xantinderivater samt anvendelse av xantinderivater for fremstilling av et terapeutisk middel mot Parkinson's sykdom

Info

Publication number
NO303265B1
NO303265B1 NO931317A NO931317A NO303265B1 NO 303265 B1 NO303265 B1 NO 303265B1 NO 931317 A NO931317 A NO 931317A NO 931317 A NO931317 A NO 931317A NO 303265 B1 NO303265 B1 NO 303265B1
Authority
NO
Norway
Prior art keywords
xanthine derivatives
group
parkinson
disease
preparation
Prior art date
Application number
NO931317A
Other languages
English (en)
Norwegian (no)
Other versions
NO931317L (no
NO931317D0 (no
Inventor
Fumio Suzuki
Junichi Shimada
Akio Ishii
Shunji Ichikawa
Original Assignee
Kyowa Hakko Kogyo Kk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyowa Hakko Kogyo Kk filed Critical Kyowa Hakko Kogyo Kk
Publication of NO931317D0 publication Critical patent/NO931317D0/no
Publication of NO931317L publication Critical patent/NO931317L/no
Publication of NO303265B1 publication Critical patent/NO303265B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • C07D473/12—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 1, 3, and 7, e.g. caffeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • C07D473/08—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 1 and 3, e.g. theophylline

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
NO931317A 1992-04-08 1993-04-06 Xantinderivater samt anvendelse av xantinderivater for fremstilling av et terapeutisk middel mot Parkinson's sykdom NO303265B1 (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP8711592 1992-04-08

Publications (3)

Publication Number Publication Date
NO931317D0 NO931317D0 (no) 1993-04-06
NO931317L NO931317L (no) 1993-10-11
NO303265B1 true NO303265B1 (no) 1998-06-22

Family

ID=13905960

Family Applications (1)

Application Number Title Priority Date Filing Date
NO931317A NO303265B1 (no) 1992-04-08 1993-04-06 Xantinderivater samt anvendelse av xantinderivater for fremstilling av et terapeutisk middel mot Parkinson's sykdom

Country Status (11)

Country Link
EP (1) EP0565377B1 (es)
JP (1) JP2613352B2 (es)
AT (1) ATE161723T1 (es)
BR (1) BR1100636A (es)
CA (1) CA2093403C (es)
DE (1) DE69316067T2 (es)
DK (1) DK0565377T3 (es)
ES (1) ES2112386T3 (es)
GR (1) GR3026233T3 (es)
HK (1) HK1001835A1 (es)
NO (1) NO303265B1 (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0585464A4 (en) * 1992-02-19 1994-03-21 Yukio Ishida HIGHLY WATER ABSORBING RICE, PROCESS FOR PRODUCING THE SAME AND USE THEREOF.
DE69331843T2 (de) * 1992-07-08 2002-09-26 Kyowa Hakko Kogyo Co., Ltd. Xanthine-Derivate als Antidepressiva
JP2613355B2 (ja) * 1992-09-28 1997-05-28 協和醗酵工業株式会社 パーキンソン氏病治療剤
AU6781194A (en) * 1993-05-03 1994-11-21 United States Of America, Represented By The Secretary, Department Of Health And Human Services, The 8-substituted 1,3,7-trialkyl-xanthine derivatives as a2-selective adenosine receptor antagonists
DE69430747T2 (de) * 1993-07-28 2003-03-06 Aventis Pharma Ltd., West Malling Verbindungen als pde iv und tnf inhibitoren
AU1823895A (en) * 1994-02-23 1995-09-11 Kyowa Hakko Kogyo Co. Ltd. Xanthine derivative
CA2262578A1 (en) * 1996-08-07 1998-02-12 Kunio Ito Fat emulsion containing xanthine derivative
US6727259B2 (en) 1997-09-05 2004-04-27 Kyowa Hakko Kogyo Co., Ltd. Remedial agent for neural degeneration
AU2002343604C1 (en) 2001-10-30 2009-09-17 Conforma Therapeutics Corporation Purine analogs having HSP90-inhibiting activity
RU2367442C2 (ru) 2003-04-25 2009-09-20 Новокардия, Инк. Способ нормализации мочеиспускания при нарушении функции почек
CN101906106A (zh) 2003-09-18 2010-12-08 康福玛医药公司 作为hsp90-抑制剂的新的杂环化合物
ES2532479T3 (es) 2004-01-28 2015-03-27 Kyowa Hakko Kirin Co., Ltd. Agentes para el tratamiento de la migraña
AU2006230447A1 (en) * 2005-03-30 2006-10-05 Conforma Therapeutics Corporation Alkynyl pyrrolopyrimidines and related analogs as HSP90-inhibitors
EP1928414A2 (en) * 2005-04-22 2008-06-11 Novacardia, Inc. Production of emulsions for intravenous injection of water-insoluble pharmaceutical compositions
KR20090094465A (ko) * 2006-12-22 2009-09-07 슈바르츠 파르마 악티엔게젤샤프트 선택적 ａ2ａ 수용체 안타고니스토로서의 8-알키닐잔틴 유도체
US7994357B2 (en) * 2009-04-03 2011-08-09 Naturewise Biotech & Medicals Corporation Cinamic compounds and derivatives therefrom for the inhibition of histone deacetylase
WO2020125779A1 (en) * 2018-12-21 2020-06-25 Sunshine Lake Pharma Co., Ltd. 8-substituted styryl xanthine derivatives and uses thereof
CN111333648B (zh) * 2019-04-24 2021-05-11 东莞市东阳光新药研发有限公司 8-取代的芳香环乙烯基黄嘌呤衍生物及其用途
CN110041331B (zh) * 2019-05-17 2020-08-07 广东东阳光药业有限公司 苯乙烯基黄嘌呤衍生物及其用途
CN112409360B (zh) * 2019-08-22 2022-12-23 广东东阳光药业有限公司 杂芳基乙烯基黄嘌呤衍生物及其用途
WO2021093701A1 (en) * 2019-11-11 2021-05-20 Sunshine Lake Pharma Co., Ltd. 8-substituted styryl xanthine derivatives and uses thereof
CN111072663B (zh) * 2019-12-12 2021-10-01 广东东阳光药业有限公司 8-取代的苯乙烯基黄嘌呤衍生物及其用途
CN111018856B (zh) * 2019-12-12 2021-10-01 广东东阳光药业有限公司 8-取代的苯乙烯基黄嘌呤衍生物及其用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA929519A (en) * 1969-07-30 1973-07-03 Schweiss Dieter Xanthine compounds and means for obtaining the same
DE3843117A1 (de) * 1988-12-22 1990-06-28 Boehringer Ingelheim Kg Neue xanthinderivate mit adenosin-antagonistischer wirkung
GB8906792D0 (en) * 1989-03-23 1989-05-10 Beecham Wuelfing Gmbh & Co Kg Treatment and compounds
DE4019892A1 (de) * 1990-06-22 1992-01-02 Boehringer Ingelheim Kg Neue xanthinderivate
FR2665636B1 (fr) * 1990-08-10 1994-10-07 Adir Utilisation d'un derive de la trimethyl-1,3,7 xanthine pour le traitement des troubles de la memoire, des troubles intellectuels de la senescence et de la maladie d'alzheimer.
WO1992006976A1 (fr) * 1990-10-18 1992-04-30 Kyowa Hakko Kogyo Co., Ltd. Derive de xanthine

Also Published As

Publication number Publication date
CA2093403A1 (en) 1993-10-09
BR1100636A (pt) 2000-04-18
NO931317L (no) 1993-10-11
HK1001835A1 (en) 1998-07-10
ES2112386T3 (es) 1998-04-01
CA2093403C (en) 1999-08-10
JPH0616559A (ja) 1994-01-25
NO931317D0 (no) 1993-04-06
GR3026233T3 (en) 1998-05-29
DE69316067D1 (de) 1998-02-12
JP2613352B2 (ja) 1997-05-28
EP0565377A1 (en) 1993-10-13
DK0565377T3 (da) 1998-03-16
EP0565377B1 (en) 1998-01-07
DE69316067T2 (de) 1998-07-02
ATE161723T1 (de) 1998-01-15

Similar Documents

Publication Publication Date Title
NO303265B1 (no) Xantinderivater samt anvendelse av xantinderivater for fremstilling av et terapeutisk middel mot Parkinson's sykdom
NO933452L (no) Et terapeutisk middel for Parkinson's sykdom
HUT68856A (en) Acridine derivatives, pharmaceutical compositions comprising the same compouds as effective substances and a process for producing the compounds and the pharmaceutical compositions
ATE232531T1 (de) Heterobizyklische derivate
DE10199003I1 (de) Substituierte Thiazolidinionderivate
DE69016899D1 (de) Thiazolidinedionederivate.
FI882813A (fi) Pyrazolopyridinfoerening och foerfarande foer dess framstaellning.
ATE226574T1 (de) 4,6-diarylpyrimidin-derivate und deren salze
ATE34976T1 (de) Arylcyclobutylalkylamine und ihre verwendung als antidepressive arzneimittel.
DE69110217D1 (de) Derivate der Kaffeinsäure und sie enthaltende pharmazeutische Zusammensetzungen.
FI893570A0 (fi) Menetelmä lääkeaineina käyttökelpoisten 1H-imidatso/1,2-b/-pyratsolin johdannaisten valmistamiseksi
FR2663026B1 (fr) Derives de [(1-arylpyrrolidin-2-yl) methyl] piperazine, leur preparation et leur application en therapeutique.
RU94038051A (ru) Гетероциклические производные, способ их получения, фармацевтическая композиция и способ лечения

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees